RETaliation - tackling rare resistance alterations to osimertinib.
Matthew G KrebsSanjay PopatPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
RET fusions occur as a rare mechanism of acquired resistance to osimertinib in epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung cancer (NSCLC) patients. Inhibiting RET alongside osimertinib shows promising clinical activity but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings.